ARTIVION, INC. 8-K

What Happened

• Artivion filed an 8‑K on May 7, 2026 disclosing that CryoLife Asia Pacific Pte. Ltd., its Singapore subsidiary, exercised the option to acquire Endospan Ltd. following FDA approval of Endospan’s Nexus™ Aortic Arch Stent Graft System (FDA approval received April 2, 2026). The option agreement originally dated September 11, 2019 was amended July 1, 2024 and January 9, 2026.
• The Agreement sets a base purchase price of $175.0 million (Artivion elected to pay all cash). After offsetting loans under the amended loan agreement, Artivion expects the net purchase price to be approximately $135.0 million. There is also contingent consideration of up to $200.0 million payable based on Nexus performance, determined about two years after closing.
• The 8‑K also incorporated a May 7, 2026 press release reporting Artivion’s financial results for Q1 2026 and announcing the exercise of the option.

Key Details

• FDA approval date for Nexus™: April 2, 2026; notice to exercise option delivered May 7, 2026.
• Base purchase price: $175.0 million (all cash elected); expected net outflow ≈ $135.0 million after loan offsets.
• Contingent earn‑out: up to $200.0 million, payable ~2 years after closing based on product performance.
• Financing: Artivion intends to fund the purchase via borrowings under its previously disclosed term loan facility (Second Amendment to Credit and Guaranty Agreement dated Sept 12, 2025).
• Governance: Endospan amended its articles to give Artivion a veto share during the option period for certain major transactions; closing remains subject to customary conditions and approvals.

Why It Matters

• This transaction would add Endospan’s Nexus aortic stent graft product to Artivion’s portfolio, potentially expanding its offerings in endovascular aortic repair. The deal size (base $175M plus up to $200M contingent) is material and may affect Artivion’s cash position and leverage since it plans to use debt financing.
• The contingent consideration ties additional payments to Nexus commercial performance, spreading some risk for Artivion but creating potential future liabilities. The acquisition is not closed yet and remains subject to due diligence, approvals and other closing conditions—investors should watch for further updates and the company’s Q1 financial disclosure for details on expected financial impacts.